TY - JOUR
T1 - Targeting Unconventional Host Components for Vaccination-Induced Protection Against TB
AU - Nemes, Elisa
AU - Khader, Shabaana A.
AU - Swanson, Rosemary V.
AU - Hanekom, Willem A.
N1 - Funding Information:
Funding. This work was supported by Washington University School of Medicine, NIH grant HL105427, AI111914-02, AI134236-02, and AI123780 to SK.
Funding Information:
This work was supported by Washington University School of Medicine, NIH grant HL105427, AI111914-02, AI134236-02, and AI123780 to SK.
Publisher Copyright:
© Copyright © 2020 Nemes, Khader, Swanson and Hanekom.
PY - 2020/7/24
Y1 - 2020/7/24
N2 - The current tuberculosis (TB) vaccine, Bacille Calmette-Guerin (BCG), is effective in preventing TB in young children but was developed without a basic understanding of human immunology. Most modern TB vaccine candidates have targeted CD4+ T cell responses, thought to be important for protection against TB disease, but not known to be sufficient or critical for protection. Advances in knowledge of host responses to TB afford opportunities for developing TB vaccines that target immune components not conventionally considered. Here, we describe the potential of targeting NK cells, innate immune training, B cells and antibodies, and Th17 cells in novel TB vaccine development. We also discuss attempts to target vaccine immunity specifically to the lung, the primary disease site in humans.
AB - The current tuberculosis (TB) vaccine, Bacille Calmette-Guerin (BCG), is effective in preventing TB in young children but was developed without a basic understanding of human immunology. Most modern TB vaccine candidates have targeted CD4+ T cell responses, thought to be important for protection against TB disease, but not known to be sufficient or critical for protection. Advances in knowledge of host responses to TB afford opportunities for developing TB vaccines that target immune components not conventionally considered. Here, we describe the potential of targeting NK cells, innate immune training, B cells and antibodies, and Th17 cells in novel TB vaccine development. We also discuss attempts to target vaccine immunity specifically to the lung, the primary disease site in humans.
KW - B cells
KW - NK cells
KW - Th17 Cells
KW - trained immunity
KW - tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85089226623&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2020.01452
DO - 10.3389/fimmu.2020.01452
M3 - Review article
C2 - 32793199
AN - SCOPUS:85089226623
SN - 1664-3224
VL - 11
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1452
ER -